When Concentra bought iTeos earlier this year, the headline number—$10.047 per share—looked underwhelming. In fact, it was at a slight discount to what the stock was trading at the day before. But buried in the fine print was something intriguing: a non‑transferable contingent value right (CVR) promising iTeos shareholders maybe more later if the company had extra cash or sold off leftover drug projects.
And iTeos isn’t alone. Cargo Therapeutics got snapped up by Concentra on nearly identical terms. Bluebird Bio entertained a CVR-heavy offer. AbbVie’s buyout of ImmunoGen included one.
So what’s going on? Why are CVRs suddenly everywhere in biotech M&A?
Simply put, a CVR is a deal sweetener that keeps both sides happy in an uncertain market.
What’s a CVR? Why Should We Care?
Let’s skip the legal jargon.
A Contingent Value Right is basically a maybe-bonus for shareholders. You sell your company (or your shares) today for a guaranteed amount, plus a promise of extra money later—if certain conditions are met.
In biotech, those conditions usually fall into two buckets:
- Performance milestones – e.g. a drug gets FDA approval, hits a sales goal, or lands a partnership.
- Cash/assets milestones – e.g. any leftover cash above a threshold will get paid out or asset sales within a set period will get shared.
The iTeos CVR is a classic example of the second type. Shareholders get all the net cash above $475M at closing plus 80% of any product sale proceeds within six months.
Here’s a quick analogy:
Say someone buys your car for cash; they then promise that if they sell the car for more within six months, they will give you a cut. If they don’t, well, you will get nothing extra.
Why Biotech Wants CVRs Now
- Too much uncertainty. Early-stage pipelines are hard to value—no one wants to overpay for a drug that might fail Phase 3.
- Cash-rich but pipeline-poor companies. After clinical failures, some biotechs (like iTeos) still sit on hundreds of millions in cash. Buyers don’t want to pay full price upfront when they don’t know how much will be left after liabilities.
- Shareholder optics. CVRs can make a lowball offer look palatable. It says, “Here’s some cash now, and we’re not shutting you out of future upside.”
But here’s the kicker: most CVRs never pay out as much as investors hope. They’re more like consolation prizes than golden tickets.
Recent Biotech CVR Examples
Here’s a simple cheat sheet comparing some of the latest deals:
| Deal | Upfront Cash | CVR Triggers | Realistic Upside? |
|---|---|---|---|
| iTeos → Concentra (2025) | $10.047/share | 100% of net cash > $475M at close + 80% of product sale proceeds (≤6 mo) | Modest. iTeos already has ~$624M, so extra above $475M likely small. |
| Cargo Therapeutics → Concentra (2025) | $4.379/share | 100% of net cash > $217.5M + 80% of product sales (≤2 yrs) | Similar “cash cleanup” deal—low upside beyond cash threshold. |
| Bluebird Bio offer (2025) | ~$4/share | Up to +$6.84/share based on future drug sales | Bigger potential payout, but entirely performance‑based. |
What’s Next
The rise of CVRs tells us something about the biotech market right now: buyers don’t want to take full risk upfront, and sellers still want credit for future potential. CVRs bridge that gap—at least on paper.
But for shareholders, they are rarely the windfall they sound like. Many expire worthless, while some trickle out small payouts. A rare few actually deliver big money.
BK talks Biopharm 